 CRANBURY, N.J., Dec. 15, 2020 GLOBE NEWSWIRE -- Rafael Pharmaceuticals, Inc. Rafael or the Company, a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration FDA has granted Fast Track designation for the Companys lead compound, CPI-613 devimistat, for the treatment of acute myeloid leukemia AML. 